A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271
Status:
Completed
Trial end date:
2016-12-12
Target enrollment:
Participant gender:
Summary
This is a single-center, randomized, placebo-controlled, double-blind, single-ascending-dose,
inpatient study to assess the safety, tolerability, and pharmacokinetics of TP-271 in healthy
subjects. Subjects aged 18 to 50 years who fulfill the inclusion/exclusion criteria will be
enrolled in this study.
Phase:
Phase 1
Details
Lead Sponsor:
Tetraphase Pharmaceuticals, Inc.
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)